

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**CONVENIENCE TRANSLATION INTO ENGLISH OF  
CONSOLIDATED FINANCIAL STATEMENTS AT 31 MARCH 2026**

**(ORIGINALLY ISSUED IN TURKISH)**

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2026**

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 31 March 2026, unless otherwise indicated.)

	<b>31 March 2026 USD (*)</b>	<b>31 March 2026 TL</b>	<b>31 December 2025 TL</b>
<b>Current assets</b>	<b>582.743</b>	<b>25.864.575</b>	<b>22.780.834</b>
Cash and cash equivalents	219.066	9.723.058	5.455.438
Financial investments	3.549	157.541	309.810
Trade receivables			
- Due from third parties	76.816	3.409.431	3.614.752
- Due from related parties	70.804	3.142.547	2.919.737
Other receivables			
- Due from third parties	915	40.614	32.098
Derivative financial assets	671	29.803	22.735
Inventories	160.034	7.102.973	8.407.929
Prepaid expenses	16.206	719.273	280.574
Current tax assets	1.161	51.542	93.098
Other current assets	33.521	1.487.793	1.644.663
<b>Non-current assets</b>	<b>1.142.317</b>	<b>50.700.720</b>	<b>52.568.868</b>
Financial investments	1.105	49.044	50.087
Investment properties	19.720	875.270	880.301
Property, plant and equipment	913.534	40.546.389	42.065.995
Right of use assets	6.345	281.599	279.933
Intangible assets and goodwill			
- Goodwill	59.147	2.625.199	2.625.199
- Other intangible assets	131.793	5.849.523	6.180.005
Prepaid expenses	10.673	473.696	487.348
<b>Total assets</b>	<b>1.725.060</b>	<b>76.565.295</b>	<b>75.349.702</b>

(\*) US Dollar ("USD") amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the official TL bid rate announced by the Central Bank of the Republic of Turkey ("CBRT") at 31 March 2026 and therefore do not form part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2026**

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 31 March 2026, unless otherwise indicated.)

	31 March 2026 USD (*)	31 March 2026 TL	31 December 2025 TL
<b>Current liabilities</b>	<b>654.944</b>	<b>29.069.157</b>	<b>26.873.944</b>
Current borrowings			
- Current borrowings from related parties	77.673	3.447.429	3.241.307
- Current borrowing to other parties	296.438	13.157.147	14.115.575
Current portion of non-current borrowings			
- Bank loans	63.274	2.808.368	2.952.265
- Lease liabilities	153	6.791	17.391
Trade payables			
- Due to third parties	136.175	6.043.998	5.034.568
- Due to related parties	14.588	647.480	500.267
Payables related to employee benefits	4.386	194.662	94.646
Other payables			
- Other payables to third parties	2.120	94.163	102.525
- Other payables to related parties	50.768	2.253.300	0
Deferred income other than contract liabilities	6.227	276.383	521.005
Current income tax liabilities	241	10.695	17.978
Current provisions			
- Current provisions for employee benefits	2.898	128.621	276.285
- Other current provisions	3	120	132
<b>Non-current liabilities</b>	<b>290.626</b>	<b>12.899.139</b>	<b>11.459.999</b>
Long-term borrowings			
- Bank loans	211.825	9.401.654	8.332.342
- Lease liabilities	3.373	149.702	153.818
Non-current provisions			
- Non-current provisions for employee benefits	7.862	348.926	374.077
Other non-current liabilities	3.281	145.611	204.599
Deferred tax liabilities	64.285	2.853.246	2.395.163
<b>Total liabilities</b>	<b>945.570</b>	<b>41.968.296</b>	<b>38.333.943</b>
<b>EQUITY</b>	<b>779.490</b>	<b>34.596.999</b>	<b>37.015.759</b>
<b>Attributable to equity holders of the parent</b>	<b>758.159</b>	<b>33.650.224</b>	<b>36.010.423</b>
Paid-in capital	87.531	3.885.000	3.885.000
Inflation adjustments on capital	199.975	8.875.689	8.875.689
Effects of business combinations under common control	1.598	70.929	70.929
Other accumulated comprehensive income/(loss) that will not be reclassified in profit and loss			
- Gains/(losses) on remeasurements of defined benefit plans	(3.758)	(166.774)	(190.513)
Other revaluation and measurement gains/losses	70	3.091	3.401
Other comprehensive income/(loss) that will be reclassified in profit and loss			
- Currency translation differences	(16.817)	(746.396)	60.283
Restricted reserves	116.862	5.186.833	4.931.394
Retained earnings	357.459	15.865.501	13.954.485
Net profit for the period	15.239	676.351	4.419.755
<b>Non-controlling interests</b>	<b>21.331</b>	<b>946.775</b>	<b>1.005.336</b>
<b>Total liabilities and equity</b>	<b>1.725.060</b>	<b>76.565.295</b>	<b>75.349.702</b>

(\*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the official TL bid rate announced by the CBRT at 31 March 2026 and therefore do not form part of these consolidated financial statements.

**CONVENIENCE TRANSLATION INTO ENGLISH OF CONSOLIDATED FINANCIAL STATEMENTS ORIGINALLY ISSUED IN TURKISH**

**AKSA AKRİLİK KİMYA SANAYİİ A.Ş.**

**FINANCIAL STATEMENTS FOR THE PERIOD ENDED 31 MARCH 2026**

(Amounts expressed in thousands of Turkish Lira ('TRY') based on the purchasing power of the Turkish Lira ("TL") as of 31 March 2026, unless otherwise indicated.)

<b>Profit or loss</b>	<b>2026 USD (*)</b>	<b>2026 TL</b>	<b>2025 TL</b>
Revenue	245.187	10.685.457	9.009.688
Cost of sales (-)	(208.667)	(9.093.868)	(7.807.761)
<b>Gross profit</b>	<b>36.520</b>	<b>1.591.589</b>	<b>1.201.927</b>
General administrative expenses (-)	(10.399)	(453.203)	(342.565)
Marketing expenses (-)	(10.202)	(444.600)	(331.675)
Research and development expenses (-)	(1.725)	(75.175)	(33.717)
Other income from operating activities	9.708	423.079	577.941
Other expense from operating activities (-)	(7.127)	(310.585)	(447.806)
<b>Profit from operating activities</b>	<b>16.775</b>	<b>731.105</b>	<b>624.105</b>
Investment activity Income	486	21.191	16.319
Share of profit/(loss) of investment accounted for using equity method	-	-	(22.172)
<b>Profit before financing income</b>	<b>17.261</b>	<b>752.296</b>	<b>618.252</b>
Finance income	12.271	534.761	502.228
Finance expense (-)	(28.928)	(1.260.694)	(915.488)
Monetary gain/(loss), net	26.207	1.142.104	338.297
<b>Profit/(loss) from continuing operations, before tax</b>	<b>26.811</b>	<b>1.168.467</b>	<b>543.289</b>
<b>Tax (expense)/income, continuing operations</b>			
- Current period tax expense (-)	(1.840)	(80.202)	(44.223)
- Deferred tax expense	(10.795)	(470.475)	(155.474)
<b>Profit from continuing operations</b>	<b>14.176</b>	<b>617.790</b>	<b>343.592</b>
<b>Attributable to:</b>			
Owners of parent	15.519	676.351	290.372
Non-controlling interests	(1.344)	(58.561)	53.220
Basic earnings per share from continuing operations (Kr)	0,14	0,16	0,16
<b>Other comprehensive income/(loss):</b>			
<b>Other comprehensive income that will not be reclassified to profit or loss</b>			
Gains /(losses) on remeasurements of defined benefit plans	717	31.236	19.646
Gains/(losses) on remeasurements of defined benefit plans of associates and joint ventures accounted for using equity method	-	-	2.184
Taxes relating to components of other comprehensive income that will not be reclassified to profit or loss	(172)	(7.497)	(4.715)
Other revaluation increases	(7)	(310)	(224)
<b>Other comprehensive income that will be reclassified to profit or loss</b>			
Other comprehensive income / (loss) related with cash flow hedges	-	-	(60.215)
Currency translation differences	(18.510)	(806.679)	53.216
Taxes relating to components of other comprehensive income that will be reclassified to profit or loss	305	11.043	36.639
<b>Total comprehensive income</b>	<b>(3.797)</b>	<b>(165.460)</b>	<b>367.936</b>
<b>Attributable to:</b>			
Owners of parent	(2.453)	(106.899)	314.716
Non-controlling interests	(1.344)	(58.561)	53.220
	<b>(3.797)</b>	<b>(165.460)</b>	<b>367.936</b>

(\*) USD amounts presented above have been translated from Turkish Lira ("TL") for convenience purposes only, at the USD average CBRT bid rates for the period ended 31 March 2026 and therefore do not form part of these consolidated financial statements.